Primary and secondary outcomes of participants
| Variable | Glibenclamide (n=28) | Placebo (n=28) | P value |
| Primary outcome | |||
| SEBES (0–2) at 10 days after medication | 17 (60.7) | 12 (42.9) | 0.181 |
| Secondary outcomes | |||
| mRS at discharge | 4 (3–5) | 3 (2–5) | 0.744 |
| mRS at 3 months | 2.5 (1–5) | 2.5 (1–5) | 0.996 |
| mRS at 6 months | 2 (1–5) | 3 (1–5) | 0.890 |
| Modified Fisher scale at 10 days after medication | 2 (1.3–3) | 2.5 (1–3.8) | 0.244 |
| Adverse events | |||
| Hypoglycaemia | 4 (14.3) | 0 (0.0) | 0.111 |
| Death at discharge | 3 (10.7) | 2 (7.1) | 1.000 |
| Cerebral hernia | 3 (10.7) | 6 (21.4) | 0.469 |
| Cerebral infarction | 6 (21.4) | 8 (28.6) | 0.537 |
| Hydrocephalus | 13 (46.4) | 7 (25.0) | 0.094 |
| Pulmonary infection | 22 (78.6) | 16 (57.2) | 0.086 |
| Liver and kidney dysfunction | 14 (50.0) | 15 (53.6) | 0.789 |
| Vasospasm | 16 (57.1) | 11 (39.3) | 0.362 |
| Decompressive craniectomy at 10 days after medicine | 1 (3.6) | 2 (7.1) | 1.000 |
| Hospital staying (days) | 17.5 (11.5–24.5) | 20.0 (11.0–29.8) | 0.806 |
Data are presented as mean±SD, median (IQR) or number of patients (%).
mRS, modified Rankin Scale; SEBES, Subarachnoid Haemorrhage Early Brain Oedema Score.